Relatlimab
Подписчиков: 0, рейтинг: 0
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Lymphocyte activation gene-3 (LAG-3) |
| Clinical data | |
| Other names | BMS-986016, relatlimab-rmbw |
| License data |
|
| Routes of administration |
Intravenous |
| Drug class | Antineoplastic |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6472H9922N1710O2024S38 |
| Molar mass | 145288.79 g·mol−1 |
Relatlimab is a monoclonal antibody designed for the treatment of melanoma. It is used in combination with nivolumab to treat melanoma.
Relatlimab is a Lymphocyte activation gene-3 (LAG-3) inhibitor. It is under development by Bristol-Myers Squibb. It is made using Chinese hamster ovary cells.
History
As of 2018, relatlimab is undergoing Phase II/III trials.
The combination nivolumab/relatlimab (Opdualag) was approved for medical use in the United States in March 2022.
Names
Relatlimab is the United States Adopted Name (USAN) and the international nonproprietary name (INN).
External links
- "Relatlimab". Drug Information Portal. U.S. National Library of Medicine.